Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 9/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | UBE2M | P61081 | 1/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314441 | 0.93 | CCR1 (0.34) | CCR1TP53MAPTPOLBUBE2M | |
| SCHEMBL13807690 | 0.93 | PTGS1 (0.34) | CCR1TP53MAPTPOLBLMNA | |
| SCHEMBL13807639 | 0.93 | MAPT (0.34) | CCR1TP53MAPTPOLBUBE2M | |
| SCHEMBL13807618 | 0.92 | UBE2M (0.32) | CCR1UBE2MDCUN1D1LMNAKCNH2 | |
| SCHEMBL13807590 | 0.92 | TP53 (0.33) | CCR1TP53MAPTPOLBUBE2M | |
| SCHEMBL13807687 | 0.90 | MAPT (0.34) | CCR1TP53MAPTPOLBLMNA | |
| SCHEMBL4312918 | 0.89 | MAPT (0.34) | CCR1TP53MAPTPOLBUBE2M | |
| SCHEMBL13807675 | 0.88 | CCR1 (0.34) | CCR1TP53MAPTPOLBUBE2M | |
| SCHEMBL13807739 | 0.87 | CCR1 (0.35) | CCR1TP53MAPTPOLBUBE2M | |
| SCHEMBL4317943 | 0.86 | TP53 (0.33) | CCR1TP53MAPTPOLBUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| WO-2007064553-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CX3CR1 | CCR1 7/4885TP53 2065/4885MAPT 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.